MEDICATION REFERENCE · REVIEW DRAFT
Tirzepatide: source schedule and units
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Reference notes
The source starts at 2.5 mg weekly for 4 weeks, then shows 2.5 mg increases after at least 4 weeks per step. Its upper amount is 15 mg weekly. These are reference values, not a personalized schedule.
The table preserves its earliest week ranges for a 10 mg vial in 2 mL, or 5 mg/mL.
| Target | Earliest weeks | Units | mL |
|---|---|---|---|
| 2.5 mg | 1–4 | 50 | 0.5 |
| 5 mg | 5–8 | 100 | 1 |
| 7.5 mg | 9–12 | 150 | 1.5 |
| 10 mg | 13–16 | 200 | 2 |
| 12.5 mg | 17–20 | 250 | 2.5 |
| 15 mg | 21 onward | 300 | 3 |
Source & content review 3 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source rounds mL separately from U-100 units. Do not silently replace its displayed values. Exact-volume calculator behavior and source-display precision require review.
- Last two rows exceed the stated vial mass; several exceed 1 mL. Preserve numbers but mark these constraints in review.
Captured source values
{
"numericalFacts": []
}